文献速递血液透析通路

血液透析通路动静脉移植物的年龄相关结局

Age-related outcomes of arteriovenous grafts for hemodialysis access.
PubMed 文献 · J Vasc Surg · 2020-02-14

基于美国肾脏数据系统2007-2014年78,341例起始血液透析患者,比较不同年龄组动静脉移植物成熟、通畅性、感染与死亡。结果显示年龄增长与移植物成熟及通畅性无显著相关,但老年组严重移植物感染需切除风险降低、死亡率升高。

要点

  • 老年患者动静脉移植物成熟时间与年轻患者无显著差异。
  • 年龄增长不显著影响移植物的一期、一期辅助及二期通畅性。
  • 老年患者严重移植物感染需切除风险降低,但死亡率升高。

核心结论

  • 在这项基于人群的血液透析队列中,高龄与移植物成熟或通畅性无显著关联,但与严重移植物感染减少及死亡率预期升高相关。

研究设计与样本

  • 回顾性队列研究,纳入美国肾脏数据系统2007-2014年所有起始血液透析的患者,共78,341例。
  • 按年龄分组:<50岁10,150例(13%),50-59岁13,167例(16.8%),60-69岁19,975例(25.5%),70-79岁20,307例(25.9%),80+岁14,742例(18.8%)。

主要发现

  • 5年一期通畅率:<50岁12%、50-59岁12%、60-69岁9%、70-79岁9%、80+岁8%(P < .001)。
  • 5年一期辅助通畅率:20% vs 21% vs 18% vs 17% vs 14%(P < .001)。
  • 5年二期通畅率:36% vs 39% vs 36% vs 30% vs 31%(P < .001)。
  • 随年龄增长,一期通畅性(aHR, 1.00; 95%CI, 1.00-1.00; P < .001)、一期辅助通畅性(aHR, 1.00; 95%CI, 1.00-1.00; P < .001)及二期通畅性(aHR, 1.00; 95%CI, 1.00-1.00; P = .029)无显著差异。
  • 与年轻患者相比,老年组严重移植物感染需切除风险降低(aHR, 0.99; 95%CI, 0.99-0.99; P < .001),死亡率升高(aHR, 1.03; 95%CI, 1.03-1.03; P < .001)。

临床怎么用

  • 高龄不应作为排除动静脉移植物作为血液透析通路的独立理由。
  • 对老年患者应个体化权衡移植物感染风险降低与死亡风险升高的预期。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The prevalence of end-stage renal disease spans the spectrum of age. Arteriovenous grafts are viable alternatives for hemodialysis access in patients whose anatomy precludes placement of an arteriovenous fistula. This report describes the age-related outcomes after arteriovenous graft placement in a population-based cohort. METHODS: A retrospective cohort study was conducted of all patients who initiated hemodialysis in the U.S. Renal Data System (2007-2014). The χ2 test, t-test, Kaplan-Meier analysis, log-rank test, and multivariable logistic and Cox regression analyses were employed to evaluate access maturation, interventions, patency, and mortality. RESULTS: Of the 78,341 patients studied, 10,150 (13%) were younger than 50 years, 13,167 (16.8%) were 50 to 59 years, 19,975 (25.5%) were 60 to 69 years, 20,307 (25.9%) were 70 to 79 years, and 14,742 (18.8%) were 80+ years. There was no significant difference in access maturation time for patients in the older age categories compared to patients younger than 50 years. Primary patency at 5 years comparing <50 years vs 50 to 59 years vs 60 to 69 years vs 70 to 79 years vs 80+ years was 12% vs 12% vs 9% vs 9% vs 8% (P < .001). Primary assisted patency at 5 years was 20% vs 21% vs 18% vs 17% vs 14% (P < .001). Secondary patency at 5 years was 36% vs 39% vs 36% vs 30% vs 31% (P < .001). There was no significant difference in primary patency (adjusted hazard ratio [aHR], 1.00; 95% confidence interval [CI], 1.00-1.00; P < .001), primary assisted patency (aHR, 1.00; 95% CI, 1.00-1.00; P < .001), and secondary patency (aHR, 1.00; 95% CI, 1.00-1.00; P = .029) with increasing age. However, there was a decrease in severe prosthetic graft infection requiring graft excision (aHR, 0.99; 95% CI, 0.99-0.99; P < .001) and increase in mortality (aHR, 1.03; 95% CI, 1.03-1.03; P < .001) for the older age categories compared with the younger patients. CONCLUSIONS: In this population-based cohort of hemodialysis patients, there was no significant association between older age and prosthetic graft maturation or patency. However, older age was associated with a decrease in severe graft infection and the expected increase in mortality.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Arhuidese IJ, Beaulieu RJ, Aridi HD, et al. Age-related outcomes of arteriovenous grafts for hemodialysis access. J Vasc Surg. 2020. PMID: 32067881. doi:10.1016/j.jvs.2019.10.096

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。